You are here: Industry Insights > Cytokinetics

News List

Cytokinetics Announces Proposed Public Offering of Common firstwordpharma
July 20, 2021
Cytokinetics, Incorporated (Nasdaq:CYTK) today announced plans to offer, subject to market and other conditions, $200,000,000 of shares of its common stock in an underwritten public offering.
Amgen, Cytokinetics, Servier Announce Continuation of GALACTIC-HF americanpharmaceuticalreview
March 05, 2020
Amgen, Cytokinetics, and Servier announced the Data Monitoring Committee (DMC) for GALACTIC-HF recently completed the second and final planned interim analysis ...
Amgen, Cytokinetics and Servier announce start of METEORIC-HF, the second Phase 3 clinical trial of omecamtiv mecarbil in patients with heart failure worldpharmanews
February 22, 2019
Amgen (NASDAQ: AMGN), Cytokinetics, Incorporated (NASDAQ: CYTK) and Servier today announced that METEORIC-HF (Multicenter Exercise Tolerance Evaluation of Omecamtiv Mecarbil Related to Increased Contractility in Heart Failure)
Cytokinetics Announces Progress Against Vision 2020 biospace
January 04, 2018
Cytokinetics, Inc. (NASDAQ: CYTK) announced today the progress associated with its 2020 vision
Cytokinetics cans lead drug after phase 3 ALS wipeout fiercebiotech
November 22, 2017
Researchers set out to learn whether tirasemtiv, a fast skeletal muscle troponin activator, could drive greater improvements on a measure of lung capacity than placebo over 24 weeks. Tirasemtiv failed to clear that bar.
Cytokinetics and Royalty Pharma sign agreement for omecamtiv mecarbil pharmaceutical-technology
February 07, 2017
Cytokinetics has signed an agreement to sell a portion of the potential royalty from Amgen on worldwide sales of omecamtiv mecarbil to Royalty Pharma.